Reading Time: 2 minutes

I have written a number of times about the role of faecal transplantation in the established intervention for Clostridium difficile and have hinted at the possible cross mechanism benefits of inducing commensal bacteria that favour tolerance into the gastrointestinal tract. The implication being, that individuals experiencing illness driven by loss of immunological tolerance, not simply within the digestive tract, but systemically may benefit from an evolutionary transplant.

Reading Time: < 1 minute

Faecal bacteriotherapy, now termed faecal microbiota transplantation (FMT), has gained prominence in light of the recent epidemic of Clostridium difficile infection (CDI) in North America and Europe. Coupled with the emergence of a hypervirulent strain of C. difficile, FMT is likely to feature prominently in the treatment of both relapsing and severe C. difficile colitis. Given that FMT is capable of successfully reversing CDI-associated colitis and is arguably the most complete and ideal probiotic, one can see the potential value of FMT in other bacteria-mediated diseases.